Guardant Health Inc (NAS:GH)
$ 29.54 0 (0%) Market Cap: 3.61 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 52.66 GF Score: 70/100

Guardant Health Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 11:00PM GMT
Release Date Price: $27.79 (+7.09%)
Ruizhi Qin
JPMorgan Chase & Co, Research Division - Analyst

All right. Good afternoon. Let's get started. I'm Julia Qin, lead analyst covering life science tools and diagnostics at JPMorgan. And it's my great pleasure to introduce you to our next company presentation by Guardant Health. And with that, let me turn it over to Helmy.

Helmy Eltoukhy
Guardant Health, Inc. - Co-Founder, Co-CEO & Chairman

Thank you, Julia, and thank you, everyone, for joining us and your interest in Guardant Health. Please note our forward-looking statement.

I would like to start our presentation, as we always do, with a patient story. These stories are the fuel that drives our relentless work and our mission to conquer cancer with data. Kirk Smith was an avid runner and cyclist, did not smoke, ate well and was in great overall shape.

Yet in December of 2013, Kirk was diagnosed with Stage 3 lung cancer at just 51 years old. His oncologist ordered his first Guardant360 test in 2017, providing actionable insights that gave Kirk access to more targeted

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot